The ImaginAb logo.

SHINE Technologies and ImaginAb Announce Lutetium-177 Clinical Supply Agreement

Press Releases

SHINE Technologies and ImaginAb Announce Lutetium-177 Clinical Supply Agreement

SHINE to supply n.c.a. Lu-177 for the clinical development of ImaginAb investigational radiopharmaceuticals

JANESVILLE, Wis., Mar. 9, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and ImaginAb Inc. (ImaginAb), a market-leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the signing of a clinical supply agreement. Under the terms of this agreement, SHINE will provide ImaginAb with highly pure, non-carrier-added (n.c.a.) lutetium-177 (Lu-177) to support the company’s preclinical and clinical needs in the development of RPTs targeting various cancers.

“We are thrilled to continue to partner with leading biotechnology companies like ImaginAb in the mission to drive innovation of cancer therapeutics,” said Greg Piefer, SHINE’s founder and CEO. “We are proud to deliver Lu-177 and other medical isotopes as they play a major role for biotechnology companies like ImaginAb to continue to innovate treatment solutions for critically ill patients.”

SHINE’s Therapeutics division produces n.c.a. Lu-177, a low-energy beta-particle emitter, which can be paired with a targeting molecule (such as an antibody or peptide) to directly target and irradiate cancer cells. SHINE’s fusion technology and proprietary medical isotope production is expected to scale without supply chain limitations experienced recently due to nuclear reactor shutdowns. The result: better meeting the needs of n.c.a. Lu-177 based therapies as they commercialize.

ImaginAb is developing radiopharmaceutical therapy agents based on proprietary minibody and cys-diabody platform technologies. This platform possesses the highly tumor target selective features of larger antibodies while offering highly tunable pharmacokinetics providing rapid clearance from non-target tissues.

Ian Wilson, CEO of ImaginAb, commented: “Having a robust supply chain is key to the implementation of radiopharmaceutical therapy, and partnering with SHINE for our Lu-177 supply offers access to what we feel will become one of the largest and most reliable sources in the world for this isotope. Lu-177 is a great fit for our platform technologies. We are very excited about our upcoming clinical programs in oncology radiopharmaceutical therapies.”

SHINE will begin supplying ImaginAb with n.c.a. Lu-177 immediately for the company’s development activities and for therapeutic clinical trials planned for 2023. More information on clinical trial results will be provided directly by ImaginAb.

About ImaginAb Inc

ImaginAb, Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapeutic agents. ImaginAb engineers antibody fragments called minibodies and cys diabodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert. Used with widely available PET imaging technology and therapeutic isotopes, these novel minibodies bind specifically to cell surface targets, providing a whole-body picture of immune activity and the potential to treat cancer. ImaginAb is advancing a pipeline of minibodies against both oncology and immunology targets.

The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, TRC, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma.

About SHINE Technologies

Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth. Want to learn more about SHINE? Follow us on social media @shinefusion and sign up for our email newsletter to follow us on our journey!

Media Contact: